Low-dose Bivalirudin in PCI for ACS Patients

Efficacy and Safety of Low-dose Bivalirudin in Percutaneous Coronary Intervention for Acute Coronary Syndrome Patients

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900024001

Enrollment

Unknown

Registered

2019-06-21

Start date

2019-08-01

Completion date

Unknown

Last updated

2019-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndrome

Interventions

Bivalirudin group:Low-dose bivalirudin only in PCI

UFH-Bivalirudin group:Low-dose bivalirudin after UFH in PCI

UFH group:UFH only in PCI

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed of acute coronary syndrome according to the 2013 ESC guidelines on the management of stable coronary artery disease; 2. aged > 18 years; 3. Stents = 1 in PCI; 4. Patients with complete clinical data.

Exclusion criteria

Exclusion criteria: 1. Chronic renal insufficiency (estimated glomerular filtration rate eGFR 2 times normal); 3. Malignant tumor, acute inflammation, blood disease; 4. heparin-induced hypochromboemia; 5. hemodynamic instability (systolic blood pressure <100mmHg; heart rate <40 beats / min; ventricular fibrillation; atrioventricular block III); 6. intraoperative aorta Intra-aortic Ballon Pump (IABP) supports treatment; 7. pregnant women; 8. taking warfarin, dabigatran etexilate or rivaroxaban; 9. active gastrointestinal bleeding, hematuria and intracranial hemorrhage within a month.

Design outcomes

Primary

Measure	Time frame
Major Adverse Cardiac Events;	—

Secondary

Measure	Time frame
Activated Coagulation Time;	—

Countries

China

Contacts

Public ContactMei Zhang

Characteristic Medical Center of People's Armed Police

307671650@qq.com+86 13752035080

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026